Tweets
Year in Review #ACR22
IVIG received FDA approval for adult dermatomyositis, shows benefit versus placebo
First approved Rx for inflammatory myositis
@RheumNow https://t.co/T6qVTQQdTp
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
Good rundown of the PRODERM trial, published @NEJM earlier this year and on my podcast (https://t.co/PzEDiBdJZn) a few eps back
I disagree w/Dr. Langford re:role in therapy. I use IVIG first line for most all pts w/myositis, grateful for the FDA approval!
#ACR22 @RheumNow https://t.co/BfHZm4Kl49
Mike Putman @EBRheum ( View Tweet )
3 years 8 months ago
Folle et al propose a neural network to differentiate RA+ & RA- vs PsA w/ AUROC 75% & 67% for RA+ vs RA- in 5 distinct hands MRI sequences. Question: what was the performance of the rheumatologist or radiologist?
https://t.co/93aZKPlKsO
Abstr#0242 #ACR22 @Rheumnow https://t.co/uk2c3gbAOT
Aurelie Najm @AurelieRheumo ( View Tweet )
3 years 8 months ago
Year in Review #ACR22
CAR T cells: deep depletion of CD19 leading to immune reset
5 patients with active SLE
Normalizations of complements, dsDNA
Drug free remission
3 will mild immune reconstitution symptoms, 1 received tocilizumab
@RheumNow
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
Nice chart w/JAKs/TYKs by drug and by cytokine pathways
In reality there is a fair bit of crossover and "selectives" aren't nearly as selective as this implies
Helpful to add deucravacitinib to the list! Looking forward to upcoming plenary
#RheumNow #ACR22 #YearInReview https://t.co/MERzpvrFB9
Mike Putman @EBRheum ( View Tweet )
3 years 8 months ago
Nice summary slide of JAK inhibitors and the history of JAKi in rheumatology,
#ACR22 #ACRambassador https://t.co/Ij2D7YikjT
Vaneet K Sandhu, MD, RhMSUS (she/her) @vksandhumd ( View Tweet )
3 years 8 months ago
Day 1 #ACR22. Tips to avoid burnout: stretch your legs, a change in scenery for virtual attendees, replenish your sweets and savoury and importantly keep your furry friend happy 🐈⬛ #PetsAtACR @RheumNow #RheumPix https://t.co/opGVSjxLjE
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 years 8 months ago
#acr22 The Rise of JAK in rheumatology
Look for Ab1117 in plenary 2 tomorrow for DEU and SLE
@RheumNow https://t.co/nLpXGyrhfJ
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
Dr. C Langford #YearinReview: RDBPCT on benefits/harms prednisolone 5 mg/day for 2 years added to SOC in 65yo+ with active RA. Results: improvement in DAS28 (0.37) but AEs occurred in 24% (infection, low bone density)—NNT 9. Study does not apply to younger pts. #ACR22 @rheumnow https://t.co/p2C6IfSje1
TheDaoIndex @KDAO2011 ( View Tweet )
3 years 8 months ago
GLORIA trial showing low-dose addon pred in older patients with RA showing modest benefit (including reduction in damage) balanced against increased AEs (mostly infection); NNH 9.5!
@RheumNow #ACR22 #yearinreview #ACRBest
Julian Segan @JulianSegan ( View Tweet )
3 years 8 months ago
Year in Review #acr22
Oral Surveillance:
With ASCVD number needed to harm 16, only 223 without ASCVD
Focus on risk stratification
@RheumNow https://t.co/tJyha1WKfR
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
ORAL surveillance the big talking factor over the last year.
NNH of 16(!) for CV event (over 5 yrs) in those with history of atherosclerotic CV disease.
@RheumNow #ACR22 #yearinreview #ACRBest
Julian Segan @JulianSegan ( View Tweet )
3 years 8 months ago
